Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boehringer ingelheim international gmbh - tiotropium bromide monohydrate 3,124 µg/dose - eq. tiotropium 2,5 µg/dose - inhalation solution - 2,5 mcg - tiotropium bromide monohydrate - tiotropium bromide

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - tiotropium bromide - inhalation solution - 2.5microgram/1dose

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

a-s medication solutions - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see warnings and precautions (5.2)] . in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warnings and precautions (5.2)]. risk summary the limited human data with spiriva handihaler use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. based on animal reproduction studies, no structural abnormalities were observed when tiotropium was

Καναδάς - Αγγλικά - Health Canada

boehringer ingelheim (canada) ltd ltee - tiotropium (tiotropium bromide monohydrate); olodaterol (olodaterol hydrochloride) - solution - 2.5mcg; 2.5mcg - tiotropium (tiotropium bromide monohydrate) 2.5mcg; olodaterol (olodaterol hydrochloride) 2.5mcg - antimuscarinics antispasmodics

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

pco manufacturing - tiotropium - inhalation solution - 2.5 microgram - tiotropium bromide

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - tiotropium, quantity: 18 microgram (equivalent: tiotropium bromide monohydrate, qty 22.5 microgram) - inhalation, powder for - excipient ingredients: lactose monohydrate - spiriva is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). spiriva is indicated for the prevention of copd exacerbations.

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - olodaterol hydrochloride 0.002736 mg/actuation eqv olodaterol; tiotropium bromide monohydrate 0.003124 mg/actuation eqv tiotropium - solution - olodaterol hydrochloride 0.002736 mg/actuation eqv olodaterol 0.0025 mg/actuation; tiotropium bromide monohydrate 0.003124 mg/actuation eqv tiotropium 0.0025 mg/actuation

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

physicians total care, inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - tiotropium bromide monohydrate 18 ug - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to ipratropium or tiotropium.  in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported. teratogenic effects, pregnancy category c. there are no adequate and well-controlled studies in pregnant women.  spiriva handihaler should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. no evidence of structural alterations was observed in rats and rabbits at inhalation tiotropium doses of up to approximately 660 and 6

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - tiotropium bromide anhydrous (unii: xx112xzp0j) (tiotropium - unii:0eb439235f) - tiotropium bromide 1.562 ug - spiriva respimat (tiotropium bromide) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva respimat is indicated to reduce exacerbations in copd patients. important limitation of use: spiriva respimat is not indicated for the relief of acute bronchospasm. spiriva respimat is a bronchodilator indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older. important limitation of use: spiriva respimat is not indicated for the relief of acute bronchospasm. spiriva respimat is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any component of this product [see warnings and precautions (5.2)] . in clinical trials with spiriva respimat, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warning